Acquired
Matched to this startup by its exact name; the buyer's report is the source.
| Acquired | Buyer | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|---|
| Reata Pharmaceuticals, Inc | Biogen Inc. | 2023 | — | $7.2 B | — | Annual report |
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $50 M | No. 4 | $50 to $250 million | equity | SEC | |
| Nov 2010 | $300 M | No. 3 | $250 million to $1 billion | equity | SEC | |
| Feb 2010 | $2 M | No. 2 | Under $2 million | equity | SEC | |
| Sep 2009 | $17 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Reata Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).
SEC Form D · Jun 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2020
That is all the official record says: Reata Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Reata Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 30 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Colin J. Meyer, M.D. | Executive officer | Jun 2020 |
| Dawn C. Bir | Executive officer | Jun 2020 |
| J. Warren Huff | Executive officer | Jun 2020 |
| Manmeet S. Soni | Executive officer | Jun 2020 |
| Michael D. Wortley | Executive officer | Jun 2020 |
| Casi M. DeYoung | Executive officer | Jul 2011 |
| Catherine M. Fanning | Executive officer | Jul 2011 |
| Colin W. Meyer | Executive officer | Jul 2011 |
| Jason D. Wilson | Executive officer | Jul 2011 |
| John M. Walling | Executive officer | Jul 2011 |
| Melean M. Visnick | Executive officer | Jul 2011 |
| Melissa W. Krauth | Executive officer | Jul 2011 |
| Paul Christian Audhya | Executive officer | Jul 2011 |
| Robert M. Kral, Jr. | Executive officer | Jul 2011 |
| William Christian Wigley | Executive officer | Jul 2011 |
| Colin A. Meyer | Executive officer | Oct 2010 |
| Eric Christian Grossman | Executive officer | Oct 2010 |
| Melissa A. Krauth | Executive officer | Oct 2010 |
| J. Kent McGaughy, Jr. | Director | Jun 2020 |
| J. Warren Huff | Director | Jun 2020 |
| Jack B. Nielsen | Director | Jun 2020 |
| James E. Bass | Director | Jun 2020 |
| William D. McCLellan, Jr. | Director | Jun 2020 |
| William E. Rose | Director | Jun 2020 |
| Dennis B. Stone | Director | Jul 2011 |
| Edward W. Rose | Director | Jul 2011 |
| James B. Bass | Director | Jul 2011 |
| Kent Christian McGaughy | Director | Jul 2011 |
| Nancy M. Wysenski | Director | Jul 2011 |
| Charles A. Sanders | Director | Oct 2010 |
Acquired (Jan 1, 2023). Acquired by Biogen Inc..